Table 2.
Demographics and basic disease characteristics of patients with MS
| RRMS | PPMS | |
| Patients (n (%)) | 39.0 (66.1) | 20.0 (33.9) |
| Age (years) (median (range)) | 45 (23–62) | 56(43–65) |
| Sex (% female) | 45.8 | 46.2 |
| Disease duration (years) (median (range)) | 14.0 (2.0–35.0) | 10.0 (3.0–37.0) |
| Time since first diagnosis (years) (median (range)) | 12.0 (1.0–30.0) | 4.5 (2.0–18.0) |
| Duration of OCR treatment (years) (median (range)) | 2.5 (0.4–8.3) | 2.4 (0.3–3.6) |
| Previous OCR cycles | 5.0 (1.0–15.0) | 5.0 (1.0–9.0) |
| EDSS at BL (median (range)) | 3.5 (0.0–6.5) | 6.0 (2.0–7.5) |
| Relapses since start of OCR | 0 | – |
| EDSS worsening since last infusion (n (%)) | – | 5/13 (38.5%) |
| Number of previous therapies (median (range)) | 2.0 (0.0–4.0) | 0.0 (0.0–2.0) |
| Last infusion to vaccination (months) (median (range)) | 4.0 (1.7–7.1) | 3.7 (0.1–12.2) |
BL, baseline; EDSS, Expanded Disability Status Scale; F/U, follow-up; MS, multiple sclerosis; OCR, ocrelizumab; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.